Use of statins after liver transplantation is associated with improved survival: results of a nationwide study.
Details
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_9E54BA86BE04
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Use of statins after liver transplantation is associated with improved survival: results of a nationwide study.
Journal
Alimentary pharmacology & therapeutics
Working group(s)
Swiss Transplant Cohort Study
Contributor(s)
Amico P., Axel A., Aubert J.D., Banz V., Sonja B., Beldi G., Berger C., Berishvili E., Binet I., Bochud P.Y., Branca S., Bucher H., Carrel T., Catana E., Chalandon Y., De Geest S., De Rougemont O., De Seigneux S., Dickenmann M., Dreifuss J.L., Duchosal M., Fehr T., Ferrari-Lacraz S., Franscini N., Garzoni C., Soccal P.G., Gaudet C., Golshayan D., Goossens N., Hadaya K., Halter J., Heim D., Hess C., Hillinger S., Hirsch H., Hirt P., Hofbauer G., Huynh-Do U., Immer F., Koller M., Laager M., Laesser B., Lehmann R., Leichtle A., Lovis C., Manuel O., Marti H.P., Martin P.Y., Martinelli M., McLin V., Mellac K., Merçay A., Mettler K., Mueller N., Müller A., Müller-Arndt U., Müllhaupt B., Nägeli M., Oldani G., Pascual M., Posfay-Barbe K., Rick J., Rosselet A., Rossi S., Rothlin S., Ruschitzka F., Schachtner T., Schanz U., Schaub S., Schnyder A., Schuurmans M., Sengstag T., Simonetta F., Stampf S., Steiger J., Stirniman G., Stürzinger U., Van Delden C., Venetz J.P., Villard J., Vionnet J., Wick M., Wilhlem M., Yerly P.
ISSN
1365-2036 (Electronic)
ISSN-L
0269-2813
Publication state
Published
Issued date
10/2022
Peer-reviewed
Oui
Volume
56
Number
7
Pages
1194-1204
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
There is limited information on the effects of statins on the outcomes of liver transplantation (LT), regarding either their use by LT recipients or donors.
To analyse the association between statin exposure and recipient and graft survival.
We included adult LT recipients with deceased donors in a nationwide prospective database study. Using a multistate modelling approach, we examined the effect of statins on the transition hazard between LT, biliary and vascular complications and death, allowing for recurring events. The observation time was 3 years.
We included 998 (696 male, 70%, mean age 54.46 ± 11.14 years) LT recipients. 14% of donors and 19% of recipients were exposed to statins during the study period. During follow-up, 141 patients died; there were 40 re-LT and 363 complications, with 66 patients having two or more complications. Treatment with statins in the recipient was modelled as a concurrent covariate and associated with lower mortality after LT (HR = 0.35; 95% CI 0.12-0.98; p = 0.047), as well as a significant reduction of re-LT (p = 0.004). However, it was not associated with lower incidence of complications (HR = 1.25; 95% CI = 0.85-1.83; p = 0.266). Moreover, in patients developing complications, statin use was significantly associated with decreased mortality (HR = 0.10; 95% CI = 0.01-0.81; p = 0.030), and reduced recurrence of complications (HR = 0.43; 95% CI = 0.20-0.93; p = 0.032).
Statin use by LT recipients may confer a survival advantage. Statin administration should be encouraged in LT recipients when clinically indicated.
To analyse the association between statin exposure and recipient and graft survival.
We included adult LT recipients with deceased donors in a nationwide prospective database study. Using a multistate modelling approach, we examined the effect of statins on the transition hazard between LT, biliary and vascular complications and death, allowing for recurring events. The observation time was 3 years.
We included 998 (696 male, 70%, mean age 54.46 ± 11.14 years) LT recipients. 14% of donors and 19% of recipients were exposed to statins during the study period. During follow-up, 141 patients died; there were 40 re-LT and 363 complications, with 66 patients having two or more complications. Treatment with statins in the recipient was modelled as a concurrent covariate and associated with lower mortality after LT (HR = 0.35; 95% CI 0.12-0.98; p = 0.047), as well as a significant reduction of re-LT (p = 0.004). However, it was not associated with lower incidence of complications (HR = 1.25; 95% CI = 0.85-1.83; p = 0.266). Moreover, in patients developing complications, statin use was significantly associated with decreased mortality (HR = 0.10; 95% CI = 0.01-0.81; p = 0.030), and reduced recurrence of complications (HR = 0.43; 95% CI = 0.20-0.93; p = 0.032).
Statin use by LT recipients may confer a survival advantage. Statin administration should be encouraged in LT recipients when clinically indicated.
Keywords
Adult, Aged, Graft Survival, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Liver Transplantation, Male, Middle Aged, Retrospective Studies, Risk Factors, Treatment Outcome, cardiovascular disease, dyslipidemia, solid organ transplantation, survival
Pubmed
Web of science
Create date
26/01/2024 11:35
Last modification date
01/03/2024 8:06
Usage data
